Robert Iannone Jazz Pharmaceuticals PLC (JAZZ) insider trading activity

Robert Iannone is EVP, Global Head of R&D & CMO of Jazz Pharmaceuticals plc. Currently has a direct ownership of 72,628 shares of JAZZ, which is worth approximately $10.2 Million. The most recent transaction as insider was on Nov 17, 2025, when has been sold 7,159 shares (Ordinary Shares) at a price of $168.26 per share, resulting in proceeds of $1,204,573. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 72.6K

8.78% 3M change

16.72% 12M change

Total Value Held $10.2 Million

Robert Iannone Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 17 2025	SELL Open market or private sale	$1,204,573 $168.26 p/Share	7,159 Reduced 8.97%	72,628 Ordinary Shares
Mar 10 2025	SELL Open market or private sale	$332,599 $138.41 p/Share	2,403 Reduced 2.93%	79,621 Ordinary Shares
Mar 07 2025	SELL Open market or private sale	$984,898 $139.11 p/Share	7,080 Reduced 7.95%	82,024 Ordinary Shares
Mar 05 2025	SELL Sale (or disposition) back to the issuer	$727,959 $138.95 p/Share	5,239 Reduced 5.55%	89,104 Ordinary Shares
Feb 27 2025	BUY Grant, award, or other acquisition	-	26,577 Added 21.98%	94,343 Ordinary Shares
Jan 17 2025	SELL Payment of exercise price or tax liability	$267,434 $122.62 p/Share	2,181 Reduced 3.12%	67,766 Ordinary Shares
Jan 17 2025	BUY Grant, award, or other acquisition	-	7,506 Added 9.69%	69,947 Ordinary Shares

Mar 05 2024	SELL Payment of exercise price or tax liability	$504,673 $117.53 p/Share	4,294 Reduced 6.46%	62,226 Ordinary Shares
Mar 01 2024	BUY Grant, award, or other acquisition	-	16,928 Added 20.29%	66,520 Ordinary Shares
Jan 17 2024	SELL Payment of exercise price or tax liability	$206,094 $119.13 p/Share	1,730 Reduced 3.37%	49,592 Ordinary Shares
Jan 17 2024	BUY Grant, award, or other acquisition	-	5,970 Added 10.42%	51,322 Ordinary Shares
Jun 05 2023	SELL Sale (or disposition) back to the issuer	$170,076 $129.73 p/Share	1,311 Reduced 2.81%	45,315 Ordinary Shares
Mar 05 2023	SELL Payment of exercise price or tax liability	$324,681 $142.78 p/Share	2,274 Reduced 4.66%	46,489 Ordinary Shares
Mar 03 2023	BUY Grant, award, or other acquisition	-	12,447 Added 20.33%	48,763 Ordinary Shares
Dec 09 2022	SELL Open market or private sale	$279,439 $151.54 p/Share	1,844 Reduced 4.83%	36,316 Ordinary Shares
Jun 06 2022	SELL Payment of exercise price or tax liability	$193,279 $149.25 p/Share	1,295 Reduced 3.29%	38,109 Ordinary Shares
Mar 05 2022	SELL Payment of exercise price or tax liability	$204,305 $153.96 p/Share	1,327 Reduced 3.27%	39,257 Ordinary Shares
Mar 03 2022	BUY Grant, award, or other acquisition	-	11,374 Added 21.89%	40,584 Ordinary Shares
Jun 05 2021	SELL Payment of exercise price or tax liability	$212,823 $176.47 p/Share	1,206 Reduced 3.98%	29,086 Ordinary Shares
Mar 05 2021	SELL Payment of exercise price or tax liability	$122,080 $164.75 p/Share	741 Reduced 2.4%	30,145 Ordinary Shares
Feb 25 2021	BUY Grant, award, or other acquisition	-	8,535 Added 21.65%	30,886 Ordinary Shares

Also insider at

ITOS

iTeos Therapeutics, Inc. Healthcare

JNCE

Jounce Therapeutics, Inc. Healthcare

Director

Robert Iannone

EVP, Global Head of R&D & CMO

Dublin 4, L2

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells JAZZ shares.

Notify only if

Value

Insider Trading

Get notified when an Jazz Pharmaceuticals PLC insider buys or sells JAZZ shares.

Notify only if

Operation

Value

Type

News

Receive news related to Jazz Pharmaceuticals plc

Track Activities on JAZZ

Account